Join Dr. Paul Kolodzik on The Second Opinion as he discusses the recent significant price drop in name-brand GLP-1 medications. In this episode, he explores the reasons behind the price reduction, what it means for patients and healthcare providers, and how this change could impact diabetes management and weight loss treatments. Tune in for expert insights and a deep dive into the factors shaping this now more accessible medication market.
